BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25559335)

  • 1. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Pietrzak RH; Ames D; Ellis KA; Harrington K; Snyder PJ; Martins RN; Masters CL; Rowe CC; Maruff P;
    Neurobiol Aging; 2015 Mar; 36(3):1239-44. PubMed ID: 25559335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
    Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
    JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aβ amyloid, cognition, and APOE genotype in healthy older adults.
    Lim YY; Ellis KA; Ames D; Darby D; Harrington K; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Villemagne VL; Maruff P;
    Alzheimers Dement; 2013 Sep; 9(5):538-45. PubMed ID: 23159043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.
    Thai C; Lim YY; Villemagne VL; Laws SM; Ames D; Ellis KA; Rainey-Smith SR; Martins RN; Masters CL; Rowe CC; Maruff P;
    PLoS One; 2015; 10(10):e0139082. PubMed ID: 26430784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing.
    Pietrzak RH; Lim YY; Ames D; Harrington K; Restrepo C; Martins RN; Rembach A; Laws SM; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    Neurobiol Aging; 2015 Mar; 36(3):1231-8. PubMed ID: 25585532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease.
    Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Porter T; Ames D; Fowler C; Rainey-Smith S; Snyder PJ; Martins RN; Salvado O; Bourgeat P; Rowe CC; Masters CL; Maruff P
    Neurology; 2016 Apr; 86(17):1635-42. PubMed ID: 27029632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Rembach A; Martins RN; Rowe CC; Masters CL; Maruff P
    Mol Psychiatry; 2015 Nov; 20(11):1322-8. PubMed ID: 25288138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
    Mormino EC; Betensky RA; Hedden T; Schultz AP; Ward A; Huijbers W; Rentz DM; Johnson KA; Sperling RA; ; ;
    Neurology; 2014 May; 82(20):1760-7. PubMed ID: 24748674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
    Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Ames D; Masters CL; Martins RN; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM
    Neurobiol Aging; 2019 Apr; 76():162-165. PubMed ID: 30716541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
    Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
    J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals.
    Lim YY; Williamson R; Laws SM; Villemagne VL; Bourgeat P; Fowler C; Rainey-Smith S; Salvado O; Martins RN; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2017; 58(4):1293-1302. PubMed ID: 28550258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.
    Buckley RF; Mormino EC; Amariglio RE; Properzi MJ; Rabin JS; Lim YY; Papp KV; Jacobs HIL; Burnham S; Hanseeuw BJ; Doré V; Dobson A; Masters CL; Waller M; Rowe CC; Maruff P; Donohue MC; Rentz DM; Kirn D; Hedden T; Chhatwal J; Schultz AP; Johnson KA; Villemagne VL; Sperling RA; ; ;
    Alzheimers Dement; 2018 Sep; 14(9):1193-1203. PubMed ID: 29803541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults.
    Hollands S; Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Harrington K; Porter T; Snyder P; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2017; 57(2):411-422. PubMed ID: 28234254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.
    Hollands S; Lim YY; Buckley R; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Lautenschlager N; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P
    J Alzheimers Dis; 2015; 43(2):677-86. PubMed ID: 25114076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults.
    Lim YY; Ellis KA; Pietrzak RH; Ames D; Darby D; Harrington K; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Villemagne VL; Maruff P;
    Neurology; 2012 Oct; 79(16):1645-52. PubMed ID: 23071163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.
    Mecca AP; Barcelos NM; Wang S; Brück A; Nabulsi N; Planeta-Wilson B; Nadelmann J; Benincasa AL; Ropchan J; Huang Y; Gelernter J; Van Ness PH; Carson RE; van Dyck CH
    Neurobiol Aging; 2018 Jan; 61():207-214. PubMed ID: 29111487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-amyloid associated differential effects of APOE ε4 on brain metabolism in cognitively normal elderly.
    Yi D; Lee DY; Sohn BK; Choe YM; Seo EH; Byun MS; Woo JI
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):961-70. PubMed ID: 24495404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.